Angeles
Castro Iglesias
Hospital de Mataró
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital de Mataró (5)
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
-
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study
HIV Medicine, Vol. 16, Núm. 10, pp. 628-634
2012
-
Long-term benefits of nevirapine-containing regimens: Multicenter study with 506 patients, followed-up a median of 9 years
Current HIV Research, Vol. 10, Núm. 6, pp. 513-520